et-loader

On the safety and efficacy of the Pfizer BioNtech Vaccine, which Costa Rica will apply from tomorrow

Share on facebook
Share on twitter
Share on whatsapp
Share on telegram
Share on email

The BNT162b2 vaccine developed by Pfizer and BioNTech was created through an innovative platform that uses messenger ribonucleic acid (mRNA). That is, instead of introducing an antigen into the body (a common method in the development of vaccines), it only introduces the genetic information of the virus through RNA molecules so that our cells can create, by themselves, the proteins that we will defend against SARS-CoV-2.

For Leandra Abarca, head of the Expanded Program of Immunizations (PAI) of the CCSS, this new form of vaccines represents a technological leap of great relevance and has several advantages, among them its safety (since they are not made with inactive viruses or parts of these), their effectiveness (they generate a solid immune response and with few side effects) and their ease of production.

«Sin lugar a duda, las vacunas constituyen una forma segura y eficaz de prevenir enfermedades y salvar vidas e impactan de manera positiva en la salud pública de las naciones porque cuando nos vacunamos no solo nos protegemos nosotros mismos sino también a quienes nos rodean. Cada persona que se vacune contra la covid-19 no solo contribuye con su propia salud, sino que nos está ayudando a disminuir la circulación de esta enfermedad en nuestro país» dijo la doctora Abarca.

Costa Rica ha firmado contratos para adquirir seis millones de dosis de la vacuna a través tres proveedores: Pfizer-BioNTech (tres millones de dosis), AstraZeneca-Oxford (un millón de dosis) y la iniciativa COVAX de la Organización Mundial de la Salud (dos millones de dosis). Estos seis millones de dosis beneficiarán a tres millones de personas y serán colocadas por los funcionarios de la CCSS a lo largo del 2021.

Latests News